Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to Lao Q and Merke DP

To the Editor:

We thank Lao Q and Merke DP for their interest in the EMQN-CAH-practice guidelines for molecular genetic testing of CAH [1] and their suggestion to include evaluation of CAH-X in routine CYP21A2 genotyping.

We completely agree with the authors of this corresponding letter that CAH-X (CAH with a hypermobility type Ehlers–Danlos syndrome (EDS) due to pathogenic tenascin-X variants) is present in a considerable number of CAH patients [2], particularly in those who carry so-called large deletions comprising also the TNXB gene. In the majority of those patients CAH-X is currently probably missed.

As addressed in previous work, the use of the CAH-MLPA assay also covering exon 35 of the TNXB-gene could help in identification of a chimeric recombination between TNXB and its pseudogene TNXA, resulting in a contiguous CYP21A2 and TNXB deletion associated with EDS (CAH-X).

So far, CAH-X diagnostic evaluation was not included in the CAH genotyping guideline, as from the EMQN-CAH scheme there is only very limited knowledge and experience concerning CAH-X genotyping. Comprehensive and reliable CAH-X genotyping would also include analysis of additional TNXB chimeras and pathogenic variants [3] not currently covered by CAH-MLPA analysis as outlined by Lao and Merke. Such CAH-X genotyping implies (i) validation as an in-house method, (ii) comprehensive understanding of the molecular background relevant for adequate interpretation of the genotyping results, (iii) the expertise of genetic counselling before and after CAH-X analysis and (iv) experience and expertise of clinical management and follow up of cardiovascular comorbidities being crucial for recognition and prevention of complications. In addition, the availability of plasma concentrations of TNX levels measured by ELISA would also be helpful.

Moreover, the respective institutions/laboratories have to define whether findings of TNXB-variants in the course of routine CYP21A2 gentoyping (in case MLPA is performed) is seen as incidental finding and to which extent such findings are communicated to the individual the blood sample of whom was analyzed (who is not necessarily a CAH patient, but may also be a healthy partner/family member). This has been controversially discussed during a previous EMQN-CAH-scheme-meeting, when a sample showed a reduced signal for TNXB.

Another important aspect in that context is that hypermobility is frequently seen and only a minority of cases is due to CAH-X. This has to be taken into account when family members or partners of CAH-patients undergo CYP21A2 genotyping. So, it can be foreseen that a considerable number of individuals who undergo CAH/CAH-X genotyping have signs and symptoms of hypermobility not related to pathogenic variants of TNXB. Thus, adequate strategies have to be developed and defined in phenotypically hypermobile individuals without CAH-X in cooperation and accordance with the respective professional societies.

We fully agree that CAH-X newborn screening would enable early diagnosis for young children before hypermobility evaluation is possible and would allow early screening for cardiac defects. In conclusion, we greatly appreciate Lao’s and Merke’s comment emphasising the importance of detecting CAH-X in patients suffering from 21-OH-defiency, as early detection and adequate therapeutic management of CAH-X will help to improve the patients’ quality of life and could prevent serious cardiac and vascular complications.

In that context it would be of major importance that further studies are performed in order to broaden the knowledge and expertise on CAH-X before including respective methods in routine diagnostic procedures.


  1. 1.

    Baumgartner-Parzer S, Witsch-Baumgartner M, Hoeppner W. EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. Eur J Hum Genet. 2020;28:1341–67.

    CAS  Article  Google Scholar 

  2. 2.

    Merke DP, Chen W, Morissette R, Xu z, Ryzin Van, Sachdev V, et al. Tenascin-X haploinsufficiency associated with Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2013;98:E379–87.

    CAS  Article  Google Scholar 

  3. 3.

    Lao Q, Brookner B, Merke DP. High-throughput screening for CYP21A1P-TNXA/TNXB chimeric genes responsible for ehlers-danlos syndrome in patients with congenital adrenal hyperplasia. J Mol Diagn. 2019;21:924–31.

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Sabina Baumgartner-Parzer.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baumgartner-Parzer, S., Witsch-Baumgartner, M. & Hoeppner, W. Reply to Lao Q and Merke DP. Eur J Hum Genet (2021).

Download citation


Quick links